---
title: "Rocket Pharma | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285621944.md"
datetime: "2026-05-07T21:15:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285621944.md)
  - [en](https://longbridge.com/en/news/285621944.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285621944.md)
---

# Rocket Pharma | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.42, missing the estimate of USD -0.4191.

EBIT: As of FY2026 Q1, the actual value is USD -48.51 M.

The provided reference, a Form 8-K filing by Rocket 制药 on May 7, 2026, indicates that the company announced certain financial information for the quarter ended March 31, 2026. However, the specific financial figures, operational metrics, or outlook/guidance are not detailed within the body of this reference document itself.

### Related Stocks

- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)

## Related News & Research

- [Why Rocket Lab (RKLB) Stock Is Down Today and Why KeyBanc Remains on the Sidelines](https://longbridge.com/en/news/286952795.md)
- [Rocket Lab Stock Price Forecast 2026 — What Financial Analysts Expect Right Now](https://longbridge.com/en/news/286931491.md)
- [Why Rocket Lab Stock Dropped Today](https://longbridge.com/en/news/286940661.md)
- ['I Wouldn't Sell,' Says Investor About Rocket Lab Stock](https://longbridge.com/en/news/286831982.md)
- [Rocket Lab (RKLB) Is Growing beyond Small Satellites. Its Backlog Is Proof](https://longbridge.com/en/news/286564146.md)